An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability

Bibliography

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• La Rosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006;91:383-92
   PubMed Web of Science ®Google Scholar
• Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18
   PubMed Web of Science ®Google Scholar
• Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99:732-8
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;93:152-60
   Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S, et al.; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705-13
   PubMed Web of Science ®Google Scholar
• Stalenhoef AFH, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26:2664-72
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR,et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006;151:975. e1-9
   PubMed Web of Science ®Google Scholar
• Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006;7:35
   PubMed Web of Science ®Google Scholar
• Middleton A, Binbrek AS, Fonseca FAH, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin 2006;22:1181-91
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
   PubMed Web of Science ®Google Scholar
• Leiter LA, Rosenson RS, Stein E, et al. on behalf of the POLARIS Study Investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007;194:e154-64
   PubMed Web of Science ®Google Scholar
• Olsson AG. Expanding options with a wider range of rosuvastatin doses. Clin Ther 2006;28:1747-63
   PubMed Web of Science ®Google Scholar
• CRESTOR Prescribing Information (US). Available at: http://www.astrazeneca-us.com/pi/crestor.pdf [Last accessed 24 September 2007]
   Google Scholar
• Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61
   PubMed Web of Science ®Google Scholar
• Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61:262-74
   PubMed Web of Science ®Google Scholar
• Schäfer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 2005;93:145-52
   PubMed Web of Science ®Google Scholar
• Monetti M, Canavesi M, Camera M, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 2007;55:441-9
   PubMed Web of Science ®Google Scholar
• McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B-32B
   PubMed Web of Science ®Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4
   PubMed Web of Science ®Google Scholar
• Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003;31:528-31
   PubMed Web of Science ®Google Scholar
• Carbonell T, Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry 2005;44:11741-8
   PubMed Web of Science ®Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28
   PubMed Web of Science ®Google Scholar
• Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41
   Google Scholar
• Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002;30:1158-63
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6
   PubMedGoogle Scholar
• Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322-9
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25:2215-24
   PubMed Web of Science ®Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553-63
   PubMed Web of Science ®Google Scholar
• Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler Suppl 2001;2:90 (Abstract P174)
   Google Scholar
• Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee MG, Cho JY, et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008;83(2):251-7
   PubMed Web of Science ®Google Scholar
• Bergman E, Forsell P, Tevell A, et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci 2006;29:205-14
   PubMed Web of Science ®Google Scholar
• Simonson SG, Martin PD, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003;58:669-75
   PubMed Web of Science ®Google Scholar
• Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001;15:211-8
   PubMed Web of Science ®Google Scholar
• CRESTOR Summary of Product Characteristics (EU). Available at: http://www.crestor.info/gUserFiles/european_prescribing_information.pdf [Last accessed 10 October 2007]
   Google Scholar
• Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112
   PubMed Web of Science ®Google Scholar
• McCormick AD, McKillop D, Butters CJ, et al. ZD4522 – an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J Clin Pharmacol 2000;40:1055
   Google Scholar
• Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005;101:9-17
   PubMed Web of Science ®Google Scholar
• Tornio A, Pasanen MK, Laitila J, et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 2005;97:104-8
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003;1:495-505
   PubMedGoogle Scholar
• Marotti M, Ming E, Gandhi SK, Pollack PS. Concomitant use of statins and CYP3A4 inhibitor drugs: data from 380 000 statin users. Eur Heart J 2006;27(Suppl 1):137 (Abstract P864)
   Google Scholar
• Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107
   PubMed Web of Science ®Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97(8A):27C-31C
   Google Scholar
• Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71
   PubMed Web of Science ®Google Scholar
• Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005;56:1-5
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaeméia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-8
   PubMed Web of Science ®Google Scholar
• Poirier A, Funk C, Lavé T, Noé J. New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Dev 2007;10:74-83
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-63
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1090-9
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Barry M. Rosuvastatin-warfarin drug interaction. Lancet 2004;363:328
   PubMedGoogle Scholar
• Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005;45:927-34
   PubMed Web of Science ®Google Scholar
• Mondillo S, Ballo P, Galderisi M. Rosuvastatin-acenocoumarol interaction. Clin Ther 2005;27:782-4
   PubMed Web of Science ®Google Scholar
• Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1352-7
   PubMed Web of Science ®Google Scholar
• Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004;57:279-86
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-97
   PubMedGoogle Scholar
• Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 2006;98:705-6
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007;192:432-7
   PubMed Web of Science ®Google Scholar
• Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-21
   PubMed Web of Science ®Google Scholar
• Bays H, Deedwania P, Jones P, et al. Comparative effect of statins on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in patients ≥65 years of age. J Am Geriatr Soc 2004;52(Suppl 4):S126
   Google Scholar
• Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41
   PubMed Web of Science ®Google Scholar
• Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383-90
   PubMedGoogle Scholar
• Brown WV, Bays HE, Hassman DR, et al.; Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43
   PubMed Web of Science ®Google Scholar
• Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-75
   PubMed Web of Science ®Google Scholar
• Olsson AG, Istad H, Luurila O, et al.; Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004;148:e4, H1-9
   PubMed Web of Science ®Google Scholar
• Kritharides L. Reducing low-density lipoprotein cholesterol – treating to target and meeting new European goals. Eur Heart J Suppl 2004;6(Suppl A):A12-8
   Google Scholar
• Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004;5:1187-200
   PubMed Web of Science ®Google Scholar
• Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007;5:177-92
   PubMedGoogle Scholar
• Insull W Jr, Ghalli JK, Hassman DR, et al. SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 2007;82:543-50
   PubMed Web of Science ®Google Scholar
• Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol 2006;13:72-6
   Web of Science ®Google Scholar
• Binbrek AS, Elis A, Al-Zaibag M, et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study). Curr Ther Res 2006;67:21-43
   PubMed Web of Science ®Google Scholar
• Bots AF, Kastelein JJ; Discovery Netherlands Investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005;59:1387-94
   PubMed Web of Science ®Google Scholar
• Fonseca FA, Ruiz A, Cardona-Muñoz EG, et al.; DISCOVERY PENTA Investigators. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005;21:1307-15
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY Study Group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004;26:1821-33
   PubMed Web of Science ®Google Scholar
• Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008;197(1):400-6
   PubMed Web of Science ®Google Scholar
• Stein EA, Strutt K, Southworth H, et al. HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003;92:1287-93
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER Study). Am J Cardiol 2007;99:673-80
   PubMed Web of Science ®Google Scholar
• Stein EA, Ose L, Retterstøl K, et al. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol 2007;1:280-6
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185-95
   PubMed Web of Science ®Google Scholar
• Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91(Suppl):3C-10C
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 2007;99:1538-43
   PubMed Web of Science ®Google Scholar
• Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 2006;98:768-73
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Clark LT, Watson KE, et al. ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006;97:229-35
   PubMed Web of Science ®Google Scholar
• Deedwania P, Ferdinand K, Lloret R, Ycas J, Stein M. Results of 3 North American trials (ARIES, IRIS, STARSHIP) comparing rosuvastatin and atorvastatin in African Americans, South Asians, and Hispanics. Atheroscler Suppl 2006;7:552 (Abstract TH-P16:267)
   Google Scholar
• Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004;64:137-51
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BHR, Franken AAM, Vincent HH; Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005;257:531-9
   PubMed Web of Science ®Google Scholar
• Sorof J, Berne C, Siewert-Delle A, Jørgensen L, Sager P; URANUS Study Investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 2006;72:81-7
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Sosef F, Duffield E. Efficacy and tolerability of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg in patients with type 2 diabetes: results from a subgroup of the EXPLORER study. Diabetologia 2006;49(Suppl 1):749 (Abstract 1240)
   Google Scholar
• Faergeman O, Sosef F, Duffield E; On Behalf of the ECLIPSE Study Investigators. LDL-C goal achievement with rosuvastatin and atorvastatin when force-titrated in patients with diabetes: results from a subgroup of the ECLIPSE study. Diab Med 2006b;23(Suppl 4):301 (Abstract 824)
   Google Scholar
• Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007;24:541-9
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dL) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007;100:1245-8
   PubMed Web of Science ®Google Scholar
• Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005;95:189-93
   PubMed Web of Science ®Google Scholar
• ter Avest E, Abbink EJ, Holewijn S, et al. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin 2005;21:1469-76
   PubMed Web of Science ®Google Scholar
• ter Avest E, Abbink EJ, de Graaf J, et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005;35:558-64
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Stein EA, Paoletti R, et al. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003;91(Suppl):25C-27C
   PubMed Web of Science ®Google Scholar
• Stender S, Schuster H, Barter P, et al. MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005;7:430-8
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Hunninghake DB, Bays HE, et al. STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005;95:360-6
   PubMed Web of Science ®Google Scholar
• Leiter LA, Palmer M, Sosef F; POLARIS Study Investigators. Efficacy of rosuvastatin 40 mg versus atorvastatin 80 mg in patients with metabolic syndrome: results from a subgroup of the POLARIS study. Diabetologia 2005;48(Suppl):A392 (Abstract 1085)
   Google Scholar
• Faergeman O, Sosef F, Duffield E; ECLIPSE Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with the metabolic syndrome as defined by the IDF: results from the ECLIPSE study. Diabetologia 2006;49(Suppl 1):745 (Abstract 1235)
   Web of Science ®Google Scholar
• Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006;27:2945-55
   PubMed Web of Science ®Google Scholar
• Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 2007;93:914-21
   PubMed Web of Science ®Google Scholar
• http://www.leeds.ac.uk/medicine/nyctru/ProjectPage_Rocket.htm
   Google Scholar
• Lablanche J-M, Tardif J-C, Benkritly A. Effects of rosuvastatin and atorvastatin on the apoB/apoA-I ratio in patients with acute coronary syndrome: the CENTAURUS study. Atheroscler Suppl 2006;7:578 (Abstract Th-P16:384)
   Web of Science ®Google Scholar
• Pitt B, Loscalzo J, Ycas J, Raichlen; for the LUNAR Study Group. Acute coronary syndromes do not lower lipid levels. J Am Coll Cardiol 2006;47(Suppl 4):(Abstract 959-186)
   PubMed Web of Science ®Google Scholar
• Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007;6:573-81
   PubMed Web of Science ®Google Scholar
• Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005;96:1290-2
   PubMed Web of Science ®Google Scholar
• Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996;16:984-91
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-53
   PubMed Web of Science ®Google Scholar
• Hatsukami TS, Zhao XQ, Kraiss LW, et al. Assessment of rosuvastatin treatment on carotid atherosclerosis in moderately hypercholesterolaemic subjects using high-resolution magnetic resonance imaging. Eur Heart J 2005;26(Suppl):626 (Abstract 3700)
   Google Scholar
• van Oostrom AJ, Plokker HW, van Asbeck BS, et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 2006;185:331-9
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Gazi IF, Filippatos TD, et al. Starting with rosuvastatin in primary hyperlipidemia – is there more than lipid lowering? Angiology 2005;56:585-92
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. The CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61
   PubMed Web of Science ®Google Scholar
• Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-7
   PubMed Web of Science ®Google Scholar
• Fellström B, Zannad F, Schmieder R, et al. AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9
   PubMedGoogle Scholar
• Tavazzi L, Tognoni G, Franzosi MG, et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to asses the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-41
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97
   PubMed Web of Science ®Google Scholar
• Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering-morning versus evening statin administration. Ann Pharmacother 2007;41:106-10
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92(Suppl):23K-29K
   PubMed Web of Science ®Google Scholar
• Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433-43
   PubMed Web of Science ®Google Scholar
• McKenney JM, ed. Report of the National Lipid Association's Statin Safety Task Force. Am J Cardiol 2006;97(Suppl 1):S1-97
   PubMed Web of Science ®Google Scholar
• Vidt DG. Statins and proteinuria. Curr Atheroscler Rep 2005;7:351-7
   PubMedGoogle Scholar
• Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602-6
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol 2006;46:1337-43
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Heintjes EM, Kastelein JJP, et al. Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006;15:435-43
   PubMed Web of Science ®Google Scholar
• McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006;15:444-53
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug Saf 2007;30:157-70
   PubMed Web of Science ®Google Scholar
• Zipes DP, Zvaifler NJ, Glassock RJ, et al. Rosuvastatin: an independent analysis of risks and benefits. MedGenMed 2006;8:73
   PubMedGoogle Scholar